Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry

Abstract

LCIG treatment led to sustained improvements in motor fluctuations, non-motor symptoms particularly sleep/fatigue, mood/cognition and gastrointestinal domains, as well as quality of life in advanced PD patients over 24 months. Safety events were consistent with the established safety profile of LCIG.